Engineered Biomimetic Nanovesicles Synergistically Remodel Folate-Nucleotide and γ-Aminobutyric Acid Metabolism to Overcome Sunitinib-Resistant Renal Cell Carcinoma
ACS Nano · 2024-10-08 · 18 (40) · 27487-27502
DOI: 10.1021/acsnano.4c08055 ↗At a glance
Journal article in ACS Nano, published online on 2024-09-27. Written by Minchao Lv and 9 co-authors. Institution: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 22…. Major MEDLINE topics: Carcinoma, Renal Cell, Drug Resistance, Neoplasm, Kidney Neoplasms, Folic Acid. Cited 17 times so far (Crossref); 72 references. Funded by: Natural Science Foundation of Shanghai Municipality, Innovative Research Team of High-level Local University in Shanghai, National Natural Science Foundation of China.
Abstract (original language)
Reprogramming of cellular metabolism in tumors promoted the epithelial-mesenchymal transition (EMT) process and established immune-suppressive tumor microenvironments (iTME), leading to drug resistance and tumor progression. Therefore, remodeling the cellular metabolism of tumor cells was a promising strategy to overcome drug-resistant tumors. Herein, CD276 and MTHFD2 were identified as a specific marker and a therapeutic target, respectively, for targeting sunitinib-resistant clear cell renal cell carcinoma (ccRCC) and its cancer stem cell (CSC) population. The blockade of MTHFD2 was confirmed to overcome drug resistance via remodeling of folate-nucleotide metabolism. Moreover, the manganese dioxide nanoparticle was proven here by a high-throughput metabolome to be capable of remodeling γ-aminobutyric acid (GABA) metabolism in tumor cells to reconstruct the iTME. Based on these findings, engineered CD276-CD133 dual-targeting biomimetic nanovesicle EMφ-siMTHFD2-MnO2@Suni was designed to overcome drug resistance and terminate tumor progression of ccRCC. Using ccRCC-bearing immune-humanized NPG model mice, EMφ-siMTHFD2-MnO2@Suni was observed to remodel folate-nucleotide and GABA metabolism to deactivate the EMT process and reconstruct the iTME thereby overcoming the drug resistance. In the incomplete-tumor-resection recurrence model and metastasis model, EMφ-siMTHFD2-MnO2@Suni reduced recurrence and metastasis in vivo. This work thus provided an innovative approach that held great potential in the treatment of drug-resistant ccRCC by remodeling cellular metabolism.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 2200/25 Xietu Rd, Shanghai 200032, China.
- Department of Otolaryngology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1678 Dongfang Rd, Shanghai 200127, China.
ORCID profiles: Minchao Lv, Jiali Zhang, Yourong Duan
Funding
- Natural Science Foundation of Shanghai Municipality
- Innovative Research Team of High-level Local University in Shanghai
- National Natural Science Foundation of China
Cite
APA
Lv, M., Liu, B., Duan, Y., Lin, J., Dai, L., Li, Y., Yu, J., Liao, J., Zhang, J., & Duan, Y. (2024). Engineered Biomimetic Nanovesicles Synergistically Remodel Folate-Nucleotide and γ-Aminobutyric Acid Metabolism to Overcome Sunitinib-Resistant Renal Cell Carcinoma. ACS Nano, 18(40), 27487-27502. https://doi.org/10.1021/acsnano.4c08055
Vancouver
Lv M, Liu B, Duan Y, Lin J, Dai L, Li Y, et al. Engineered Biomimetic Nanovesicles Synergistically Remodel Folate-Nucleotide and γ-Aminobutyric Acid Metabolism to Overcome Sunitinib-Resistant Renal Cell Carcinoma. ACS Nano. 2024;18(40):27487-27502. doi:10.1021/acsnano.4c08055
BibTeX
@article{Lv2024,
author = {Lv, Minchao and Liu, Bin and Duan, Yi and Lin, Jiangtao and Dai, Li and Li, Yuanyuan and Yu, Jian and Liao, Jinghan and Zhang, Jiali and Duan, Yourong},
title = {Engineered Biomimetic Nanovesicles Synergistically Remodel Folate-Nucleotide and γ-Aminobutyric Acid Metabolism to Overcome Sunitinib-Resistant Renal Cell Carcinoma},
journal = {ACS Nano},
year = {2024},
volume = {18},
number = {40},
pages = {27487--27502},
doi = {10.1021/acsnano.4c08055}
}
EUVIMED